跳转至内容
Merck
CN

SML2237

Sigma-Aldrich

Ormeloxifene

≥95% (HPLC), SERM modulator, film or powder or oil

别名:

(trans)-1-[2-[p-(7-methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy]ethyl]pyrrolidine, 3,4-trans-2,2-Dimethyl-3-phenyl-4-[p-(β-pyrrolidinoethoxy)phenyl]-7-methoxychroman, Centchroman, rel-1-[2-[4-[(3R,4R)-3,4-Dihydro-7-methoxy-2,2-dimethyl-3-phenyl-2H-1-benzopyran-4-yl]phenoxy]ethyl]pyrrolidine, trans-Centchroman

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C30H35NO3
化学文摘社编号:
31477-60-8
分子量:
457.60
MDL编号:
MFCD05662186
UNSPSC代码:
12352200
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Ormeloxifene, ≥95% (HPLC)

方案

≥95% (HPLC)

表单

film or powder (or oil)

颜色

colorless to yellow-white

储存温度

2-8°C

SMILES字符串

CC([C@@H](C1=CC=CC=C1)[C@@H]2C3=CC=C(OCCN4CCCC4)C=C3)(C)OC5=C2C=CC(OC)=C5

InChI

1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m1/s1

InChI key

XZEUAXYWNKYKPL-WDYNHAJCSA-N

相关类别

生化/生理作用

Ormeloxifene (Centchroman) is a non-steroidal selective estrogen receptor modulator (SERM) that exhibit anticancer activity. Ormeloxifene suppresses the ovariectomy-induced bone resorption in rats.
non-steroidal selective estrogen receptor modulator (SERM)

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000049961
0000049960
0000038445

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Geetika Kharkwal et al.
Journal of molecular endocrinology, 48(3), 261-270 (2012-04-12)
Ormeloxifene (Orm), a triphenylethylene compound, has been established as a selective estrogen receptor modulator (SERM) that suppresses the ovariectomy-induced bone resorption in rats. However, the precise mechanism underlying the bone-preserving action of Orm remains unclear. In this study, we evaluated
William R Surin et al.
Journal of basic and clinical physiology and pharmacology, 1-8 (2014-01-29)
Abstract Background: Cancer is one of the leading causes of morbidity and mortality globally. Cancer-associated thrombosis is well established in clinical settings, and thrombin has been found to induce angiogenesis at cancer sites. This establishes a link between cardiovascular diseases
Bilal Bin Hafeez et al.
Molecular cancer therapeutics, 16(10), 2267-2280 (2017-06-16)
Ormeloxifene is a clinically approved selective estrogen receptor modulator, which has also shown excellent anticancer activity, thus it can be an ideal repurposing pharmacophore. Herein, we report therapeutic effects of ormeloxifene on prostate cancer and elucidate a novel molecular mechanism

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持